Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal International Journal Of Health And Social Behavior
Fayza Nurrahmi
Universitas Jambi
Health Professions Nursing Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Rationality of ACE-Inhibitor Use in Hypertension Patients at Community Health Center Simpang IV Sipin in Jambi City, During 2023-2024 Fayza Nurrahmi; Mara Imam Taufiq Siregar; Anggelia Puspasari; Indrianti Indrianti; Budi Justitia
International Journal of Health and Social Behavior Vol. 3 No. 3 (2026): August: International Journal of Health and Social Behavior
Publisher : Asosiasi Riset Ilmu Kesehatan Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.62951/ijhsb.v3i3.657

Abstract

Hypertension is a chronic disease with a high global prevalence and a major risk factor for cardiovascular complications. Angiotensin-Converting Enzyme Inhibitors (ACE-Is) are widely recommended as first-line antihypertensive therapy, making evaluation of their rational use essential to ensure treatment safety and effectiveness. This descriptive observational study employed a retrospective design using medical records of hypertensive outpatients at Puskesmas Simpang IV Sipin, Jambi, from January 2023 to December 2024. A total of 100 eligible patients were included. The evaluation assessed the appropriateness of indication, dosage, frequency, duration of therapy, and potential drug interactions based on World Health Organization (WHO) criteria and the JNC 8 guidelines. Most patients were aged 60 years or older and were diagnosed with essential hypertension or hypertensive heart disease. All ACE-I prescriptions were appropriate for their clinical indications (100%), while dosage, frequency, and treatment duration fully complied with guideline recommendations. Most identified drug interactions were synergistic, whereas antagonistic (11%) and potentiation (25%) interactions were generally mild to moderate and clinically manageable. Overall, ACE-I prescribing was considered rational. Continuous monitoring remains important, particularly for patients at risk of clinically significant drug interactions to optimize therapeutic outcomes and patient safety.
Co-Authors Anggelia Puspasari Budi Justitia Indrianti Indrianti Mara Imam Taufiq Siregar